张思龙简介

【个人简介】

张思龙，男，理学博士，一流学科特聘教授A类，硕士生导师，贵州省药学会青委会委员，贵州省高校医院科研院所创新人才项目（自然科学领域）“优秀青年人才”，获2025全国科算智药创新创业大赛（新华网主办）三等奖，中国国际大学生创新大赛2024贵州省赛决赛金奖（第一指导老师），第十四届“挑战杯”贵州省大学生创业计划竞赛一等奖（第一指导老师）。

课题组主要从事靶点结构的小分子药物设计、合成及早期成药性评价研究。重点开展了基于外源性机制的蛋白降解剂和小分子靶向抑制剂的研究工作，近几年发表中科院一区文章15篇，包括药化顶级top1 期刊J Med Chem 8 篇。目前主持国家自然科学基金2项（面上1项）。

邮箱：silongzhang@whu.edu.cn

【主持项目】

1.   国家自然科学面上项目，基于化学降解机制SOS1降解剂的构建、可控媒介的探究及其抗KRAS驱动型胰腺癌活性研究，2026/01-2029/12，49万；

2.   国家自然科学青年基金项目，单线态氧介导的可控化雌激素受体α光敏降解剂的构建及其抗乳腺癌活性研究，2023/01-2025/12，30万（已结题）；

3.   贵州大学自然科学专项（特岗）科研基金项目，基于化学降解机制的SOS1降解剂的构建、作用媒介的探究及其抗肿瘤活性研究，2023/07-2027/07，80万；

【学术论文】

1. Hu L.L.; Zhang Y.; Wang Z.W.; Qing, L. L.; Yang Y.L.; Lu X.; Yu Q.*; He H.*; Zhang S.L.* Dual inhibition of ERα/NF-κB pathways coupled with sonodynamic therapy via a multifunctional AIEgen. Chem. Commun.2026, 62, 4783-4786

2. Zhang, Y.; YuQ.Y.; Wang, Z. W.; Qing, L. L.; Mo X.M.; Liu B.; Chai Y.E.; Yu B.Q.; Dong Y.X.; Pan W.D.*; Zhang, S. L.*; He H.* Rational design of methylene blue−raloxifene conjugates for efficient breast tumor elimination triggered by ERα degradation. J. Med. Chem.2025, 68, 8861-8872.

3. Li Q.Z.; Lu X.; Yang Y.L.; Li T. Y.; Chen X. H.; Yuan R.M.; Ding X.*; Zhang S.L.*; He H.* A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer. Chem. Commun. 2025, 61, 9693-9696.

4. Qing L. L.^#; Yu Q. Y. ^#; Wang C. Q.; Lu X.; Yang Y. L.; Chen X.; Li X. X.; Min J.; Pan W. D.; He H. *; Zhang H. *; Zhang S.L.*. Discovery of D‑ring-contracted artemisinin as a potent hydrophobic tag for targeted protein degradation. J. Med. Chem.2025, 68, 1619-1631.

5. Qing L. L.; Cheng Z, Z.; Xu J.; Wang Z. W.; Li Y. Y.; Gauthier M.; Zhang S.L.*; He H.*. Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: A joint view of experiments and simulations. Eur. J. Med. Chem.2025, 282, 117065.

6. Lu X.; Wang Z. W.; Zhang Y.; Meng T.; Chen X. H.; Yuan R. Y.; Liu B.; He H.*; Ding X.*; Zhang S.L.*. A curcumin-based HDACs inhibitor for targeted sonodynamic therapy of breast cancer. Int. J. Biol. Macromol.2025, 287, 138616.

7. He H.; Wang Z. W.; Peng X. K.: Qing L. L.; Zhang Y.; Fu S. J.; Xu J.; Li Y. Y.*; Zhang S.L.*. Identification of a sonically activated degrader of methionine adenosyltransferase 2A by an in silico approach assisted with the hole−electron analysis. J. Med. Chem. 2024,67,543-554.

8. Xu J.; Zhao A.; Chen D.; Wang J.; Ma J.; Qing L. L.; Li Y. Y.; Fang H. X.; He H.*; Pan W. D.*; Zhang S. L.*Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability. Eur. J. Med. Chem.2024, 266, 116160.

9. Li Y. Y.; Sun M.; Yu J.; Jiang W.; Tian W.; Chen X.; Zhang S. L.*; He H.*. Design of sonosensitizers integrated with resveratrol motif for synergetic sonodynamic therapy and NF-κB transcription suppression of breast cancer. J. Med. Chem. 2023, 66,6149-6159.

10. He H.; Chen R. Q.; Wang Z. W.; Qing L. L.; Zhang Y.; Liu Y.; Pan W. D.*;Fang H. X.*; Zhang S. L.*. Design of orally-bioavailable tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR. Bioorg. Chem.2023, 136,106536.

11. Zhang S. L.; Qing L. L.; Wang Z. W.; Zhang Y.; Li Y. Y.; Fang H. X.*; Liu Y.; He H.*. Design and structural optimization of methionine adenosyltransferase 2A (MAT2A) inhibitors with high in-vivo potency and oral bioavailability. J. Med. Chem.2023, 66,4849-4867.

12. Zhang S. L. ^#*; Li Y. Y.^#; Li T.; Zhang Y.; Li H. M.; Cheng Z. Z.; Peng N.; Liu Y.; Xu J. *; He H.*. Activable targeted protein degradation platform based on light-triggered singlet oxygen. J. Med. Chem.2022, 65, 3632-3643.入选ESI“高被引论文”.

13. Zhang S.L.; Zhang Y.; Chen X.; Xu J.; Fang H. X.; Li Y. Y. *; Liu Y.*; He H.*. Design and structural optimization of orally-bioavailable SOS1 inhibitors for the treatment of KRAS-driven carcinoma. J. Med. Chem.2022, 65 (23), 15856-15877.

14. He H.; Zhang Y.; Xu J.; Li Y. Y.; Fang H. X. *; Liu Y. *;Zhang S. L.*. Discovery of orally-bioavailable SOS1 inhibitors for suppressing KRAS-driven carcinoma. J. Med. Chem.2022, 65 (19), 13158-13171.

15. Zhang Y.; Ding X.; Xie F.; Gao M. J.; Qiu J. L.; Wang Z. Y.; Qing L. L.; Yan J. Q.; Li Y. Y.; Xu J.; Jiao Y. H.; Liu Y.*; He H.*; Zhang S. L.*.Targeted recruitment and degradation of estrogen receptor α by photothermal polydopamine nanoparticles for breast tumor ablation. Adv. Healthc. Mater. 2022, 11, 2200960.

16. Li T.; Zhang Y.; Wang Z. W.; Qing L. L.; Zhang L. J. Peng N.; Liu Y. *;Zhang S. L.*; He H.*. AIEgen based turn-on fluorescent probes of histone deacetylase 6 via restriction of molecular motion. Sensor Actuat. B-Chem.2022, 364, 131882.

【授权专利】

1. 张思龙；钟杭；何欢；潘卫东；卿罗龙；王昌琦；陈晓；吴昱萱；李香香；一种以青蒿素类似物作为疏水标签的靶向蛋白降解剂及其制备方法和应用，申请日期：2024-09-12，申请号：2024112728920。

2. 张思龙；何欢；张彧；王子威；潘卫东；一种以亚甲基蓝类似物作为单线态氧靶向蛋白降解标签的2-（4-羟苯基）苯并噻酚类化合物及其应用，申请日期：2024-06-16，申请号：2024107720007。